Research paper| Volume 24, ISSUE 2, P58-66, May 2019

Download started.


“I'm obviously not dying so it's not something I need to sort out today”: Considering hepatitis C treatment in the era of direct acting antivirals

Published:November 28, 2018DOI:


      • Availability of DAA medications in and of themselves is not enough to ensure people will come forward for HCV treatment.
      • Understanding the preferred models of HCV care for people who inject drugs can ensure adequate scale up of treatment.
      • Understanding the needs of those who have yet to engage in HCV care will be crucial in continuing the treatment momentum.



      People who inject drugs are the group at greatest risk of hepatitis C virus (HCV) infection. The advent of new direct-acting antiviral (DAA) treatment provides opportunities for increased uptake of therapy.


      We conducted in-depth interviews with thirty HCV positive participants from the SuperMIX cohort study. Interviews were transcribed, coded, and analysed for emerging themes and similarities between participants. General descriptions and critical interpretation of themes were generated and selective quotes extracted verbatim to best illustrate the critical themes.


      Participants described their experiences of living with HCV, their knowledge of HCV treatment accessibility, and information on the types of support ain themes: Understanding the need for treatment; Knowledge and framing of treatment access; and Support during treatment.


      The new, highly effective DAAs for the treatment of HCV are heralded as the potential beginning of HCV elimination, especially in settings where scale up is high. Our data from active PWID show that the availability of DAA medications in and of themselves is likely not to be enough to ensure that PWID will come forward for HCV treatment in sufficient numbers to drive elimination.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Infection, Disease & Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mohd Hanafiah K.
        • Groeger J.
        • Flaxman A.D.
        • Wiersma S.T.
        Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.
        Hepatology. 2013; 57: 1333-1342
        • World Health Organisation
        Global hepatitis report.
        WHO, Geneva2017
        • Hajarizadeh B.
        • Grebely J.
        • McManus H.
        • Este C.
        • Razavi H.
        • Gray R.T.
        • et al.
        Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment.
        J Gastroenterol Hepatol. 2017; 32: 229-236
        • Institute T.K.
        Monitoring hepatitis C treatment uptake in Australia (Issue 9). vol. 9. The Kirby Institute, UNSW, Sydney2018
        • Shepard C.W.
        • Finelli L.
        • Alter M.J.
        Global epidemiology of hepatitis C virus infection.
        Lancet Infect Dis. 2005; 5: 558-567
        • Wade A.J.
        • Macdonald D.M.
        • Doyle J.S.
        • Gordon A.
        • Roberts S.K.
        • Thompson A.J.
        • et al.
        The cascade of care for an Australian community-based hepatitis C treatment service.
        PLoS One. 2015; 10e0142770
        • Talal A.H.
        • Thomas D.L.
        • Reynolds J.L.
        • Khalsa J.H.
        Toward optimal control of hepatitis C virus infection in persons with substance use disorders.
        Ann Intern Med. 2017; 166: 897-898
        • Aspinall E.J.
        • Corson S.
        • Doyle J.S.
        • Grebely J.
        • Hutchinson S.J.
        • Dore G.J.
        • et al.
        Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.
        Clin Infect Dis. 2013; 57: S80-S89
        • Iversen J.
        • Grebely J.
        • Topp L.
        • Wand H.
        • Dore G.
        • Maher L.
        Uptake of hepatitis C treatment among people who inject drugs attending Needle and Syringe Programs in Australia, 1999–2011.
        J Viral Hepat. 2014; 21: 198-207
        • Ford C.
        • Bressan J.
        Ending the mass criminalisation of people who use drugs: a necessary component of the public health response to hepatitis C.
        BMC Infect Dis. 2014; 14: S4
        • Harris M.
        • Jolley E.
        • Martin A.
        • Wells H.
        • Rhodes T.
        Barriers and facilitators to hepatitis C treatment for people who inject drugs: a qualitative study.
        WHO Regional Office for Europe, Denmark2012
        • Hellard M.
        • Sacks-Davis R.
        • Gold J.
        Hepatitis C treatment for injection drug users: a review of the available evidence.
        Clin Infect Dis. 2009; 49: 561-573
        • Higgs P.
        • Sacks-Davis R.
        • Gold J.
        • Hellard M.
        Barriers to receiving hepatitis C treatment for people who inject drugs: myths and evidence.
        Hepat Mon. 2011; 11: 513-518
        • Treloar C.
        • Rance J.
        • Dore G.J.
        • Grebely J.
        • the E.S.G.
        Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
        J Viral Hepat. 2014; 21: 560-567
        • Millman A.J.
        • Ntiri-Reid B.
        • Irvi R.
        • Kaufmann M.H.
        • Aronsohn A.
        • Duchin J.S.
        • et al.
        Barriers to treatment access for chronic hepatitis C virus infection: a case series.
        Top Antivir Med. 2017; 25: 110-113
        • Grebely J.
        • Bruneau J.
        • Bruggmann P.
        • Harris M.
        • Hickman M.
        • Rhodes T.
        • et al.
        Elimination of hepatitis C virus infection among PWID: the beginning of a new era of interferon-free DAA therapy.
        Int J Drug Pol. 2017; 47: 26-33
        • The Kirby Institute
        Monitoring hepatitis C treatment uptake in Australia (Issue 7).
        The Kirby Institure, UNSW, Sydney2017
        • Aronsohn A.
        • Jensen D.
        Informed deferral: a moral requirement for entry into the hepatitis C virus treatment warehouse.
        Hepatology. 2012; 56: 1591-1592
        • Memedovic S.
        • I.J.
        • Geddes L.
        • Maher L.
        Australian needle syringe program survey national data report 2012–2016: prevalence of HIV, HCV and injecting and sexual behaviour among NSP attendees.
        Kirby Institute, UNSW, Sydney2017
        • Hellard M.
        • Sacks-Davis R.
        • Doyle J.
        Hepatitis C elimination by 2030 through treatment and prevention: think global, act in local networks.
        J Epidemiol Community Health. 2016; 70: 1151-1154
        • Hellard M.
        • Rolls D.A.
        • Sacks-Davis R.
        • Robins G.
        • Pattison P.
        • Higgs P.
        • et al.
        The impact of injecting networks on hepatitis C transmission and treatment in people who inject drugs.
        Hepatology. 2014; 60: 1861-1870
        • Hellard M.
        • Doyle J.S.
        • Sacks-Davis R.
        • Thompson A.J.
        • McBryde E.
        Eradication of hepatitis C infection: the importance of targeting people who inject drugs.
        Hepatology. 2014; 59: 366-369
        • Wade A.J.
        • Macdonald D.
        • Doyle J.S.
        • Thompson A.J.
        • Roberts S.K.
        • Hellard M.E.
        Successful community based treatment of hepatitis C in people who inject drugs.
        J Hepatol. 2015; 62: S653
        • Jain M.K.
        • Thamer M.
        • Therapondos G.
        • Shiffman M.L.
        • Kshirsagar O.
        • Clark C.
        • et al.
        Has access to HCV therapy changed for patients with mental health or substance use disorders in the DAA period?.
        Hepatology. 2018;
        • Nguyen P.
        • Vutien P.
        • Hoang J.
        • Trinh S.
        • Le A.
        • Yasukawa L.A.
        • et al.
        Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.
        BMJ Open Gastroenterol. 2017; 4
        • Higgs P.
        • Wright C.
        • Hellard M.
        Letter: new treatments for hepatitis C have implications for quality of life in people who inject drugs.
        Aliment Pharmacol Ther. 2016; 43: 840-841
        • Aitken C.K.
        • Lewis J.
        • Tracy S.L.
        • Spelman T.
        • Bowden D.S.
        • Bharadwaj M.
        • et al.
        High incidence of hepatitis C virus reinfection in a cohort of injecting drug users.
        Hepatology. 2008; 48: 1746-1752
        • Horyniak D.
        • Higgs P.
        • Jenkinson R.
        • Degenhardt L.
        • Stoove M.
        • Kerr T.
        • et al.
        Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results.
        Harm Reduct J. 2013; 10: 11
        • Rice J.P.
        Hepatitis C treatment: back to the warehouse.
        Clin Liver Dis. 2015; 6: 27-29
        • Gunn J.
        • Higgs P.
        OST dispensing pharmacies play a role in HCV elimination too.
        J Am Pharm Assoc. 2018; 58: 245
        • Lim M.S.C.
        • Hocking J.S.
        • Hellard M.E.
        • Aitken C.K.
        SMS STI: a review of the uses of mobile phone text messaging in sexual health.
        Int J STD AIDS. 2008; 19: 287-290
        • Read P.
        • Lothian R.
        • Chronister K.
        • Gilliver R.
        • Kearley J.
        • Dore G.J.
        • et al.
        Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
        Int J Drug Pol. 2017; 47: 209-215
        • Henderson C.
        • Madden A.
        • Kelsall J.
        ‘Beyond the willing & the waiting’ — the role of peer-based approaches in hepatitis C diagnosis & treatment.
        Int J Drug Pol. 2017; 50: 111-115
        • World Health Organization
        Guidelines for the screening, care and treatment of persons with chronic hepatitis C infection: policy Brief.
        World Health Organization, Geneva, Switzerland2016
        • Rance J.
        • Newland J.
        • Hopwood M.
        • Treloar C.
        The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
        Soc Sci Med. 2012; 74: 245-253
        • Harris M.
        • Rhodes T.
        • Martin A.
        Taming systems to create enabling environments for HCV treatment: negotiating trust in the drug and alcohol setting.
        Soc Sci Med. 2013; 83: 19-26